STXS Stereotaxis, Inc.
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1289340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.8%
TTM net income YoY5.4%
TTM EPS YoY14.3%
Revenue 3-yr CAGR2.2%
Net income 3-yr CAGR—
Margins
Gross margin52.5%
Operating margin-71.9%
Net margin-70.9%
FCF margin-49.2%
EBITDA margin-69.6%
Returns
ROE-161.7%
ROA-35.0%
ROIC (approx.)-229.4%
Asset turnover0.49x
Leverage & solvency
Liabilities / assets67.7%
Debt / equity0.12x
Current ratio1.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $32.38M | $26.92M |
| Cost of revenue | $15.31M | $12.32M |
| Gross profit | $17.07M | $14.59M |
| R&D expense | $9.38M | $9.76M |
| SG&A expense | $17.85M | $17.20M |
| Operating income | -$22.11M | -$24.74M |
| Net income | -$21.64M | -$24.05M |
| EBITDA | -$21.49M | -$24.15M |
| EPS (basic) | -0.25 | -0.30 |
| EPS (diluted) | -0.25 | -0.30 |
| Weighted avg. shares (diluted) | 90.96M | 85.18M |
| Banking | ||
| Net interest income | $467,000 | $694,000 |
| Balance sheet | ||
| Cash & equivalents | $13.42M | $12.22M |
| Short-term investments | $0 | $0 |
| Receivables | $5.85M | $3.82M |
| Inventory | $9.57M | $8.33M |
| Current assets | $33.85M | $26.44M |
| PP&E, net | $3.02M | $3.57M |
| Goodwill | $3.76M | $3.76M |
| Intangibles | $6.43M | $7.36M |
| Total assets | $52.25M | $46.72M |
| Current liabilities | $22.36M | $21.60M |
| Total liabilities | $33.53M | $35.29M |
| Shareholders' equity | $13.48M | $6.08M |
| Cash flow statement | ||
| Operating cash flow | -$13.69M | -$8.50M |
| Capital expenditure | $93,000 | $34,000 |
| Free cash flow | -$13.78M | -$8.53M |
| Investing cash flow | -$93,000 | $74,000 |
| Financing cash flow | $14.76M | $297,000 |
| Depreciation & amortization | $626,000 | $587,000 |
| Stock-based compensation | $9.85M | $10.26M |
| Dividends paid | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.